Core Insights - Lantern Pharma Inc. will present at the 7th Glioblastoma Drug Development Summit in Boston from February 17-19, 2026, focusing on its AI-driven oncology drug development [1] - The company’s RADR® platform has facilitated the development of LP-184 / STAR-001, a novel therapeutic candidate for CNS cancers, including recurrent glioblastoma and pediatric brain tumors [1] - STAR-001 has received both FDA Orphan Drug Designation and Rare Pediatric Disease Designation, highlighting its potential in treating rare conditions [1] Company Overview - Lantern Pharma is a clinical-stage biopharmaceutical company utilizing artificial intelligence and machine learning to enhance oncology drug discovery and development [1] - The RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug responses, and design more effective clinical trials [1] - The company’s pipeline includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations [1] Presentation Highlights - CEO Panna Sharma will discuss the application of RADR® in discovering novel combination therapies, selecting optimal cancer indications, identifying patient biomarkers, and elucidating the mechanism of action of STAR-001 during the summit [1] - The presentation will emphasize AI-driven insights that address challenges in treating aggressive brain cancers like glioblastoma and atypical teratoid/rhabdoid tumors (ATRT) [1]

RT Dr James Davies (PhD) 💭 (@JDaviesPhD)This study finds that psychiatrists who worked on DSM-5 received $14M in undisclosed funding from the pharmaceutical industry; the very industry that has profited enormously from DSM's over-medicalisation of everyday life.https://t.co/PDbcRKrt5k ...

The pharmaceutical executive, who forfeited the album after a securities-fraud conviction, claims he still has copyright ownership. https://t.co/exEFAYoHYR ...

really Lily's gain. Let's ask Guggenheim, managing director and pharma analyst Sheamus Fernandez. Sheamus, thanks for coming back on.Um, if one's winning, I don't want to say one's losing, but if one is doing better than the other, does that mean people are shifting their GLP1 drug of choice. >> Yeah, it's a great question, Brian. Look, I I don't think that we're seeing a lot of market shifts just yet uh in terms of their their drug of choice. We're seeing a huge market expansion in general occur.I think th ...

Core Insights - Cencora reported a revenue of $85.9 billion for the first quarter of fiscal 2026, marking a 5.5% increase year-over-year, driven by growth in both U.S. and International Healthcare Solutions segments [1][2] - The company achieved a GAAP diluted EPS of $2.87, up 14.8% from $2.50 in the prior year, while adjusted diluted EPS rose 9.4% to $4.08 [1][3] - Cencora raised its adjusted operating income guidance for fiscal 2026 to a growth range of 11.5% to 13.5%, reflecting the acquisition of OneOncology and strong performance in the U.S. Healthcare Solutions segment [1][2] Financial Performance - Revenue for the U.S. Healthcare Solutions segment was $76.2 billion, a 5.0% increase year-over-year, attributed to market growth and increased sales of specialty products [2] - International Healthcare Solutions segment revenue reached $7.6 billion, up 9.6% year-over-year, primarily due to growth in the European distribution business [2] - Operating income for the U.S. Healthcare Solutions segment increased by 21.0% to $831.3 million, while the International Healthcare Solutions segment saw a decrease of 13.9% in operating income to $142.2 million [2] Segment Analysis - The U.S. Healthcare Solutions segment's growth was driven by unit volume growth and increased sales of diabetes and weight loss products, despite some losses from specific customers [2] - The International Healthcare Solutions segment's revenue growth was 6.2% on a constant currency basis, but operating income decreased by 17.0% due to challenges in the European distribution business [2] - Revenue from other businesses, including MWI Animal Health and Profarma, was $2.1 billion, reflecting a 6.3% increase, although operating income in this category decreased by 6.1% [2] Guidance and Expectations - Cencora reaffirmed its full fiscal 2026 adjusted diluted EPS guidance range of $17.45 to $17.75, reflecting the expected contributions from the OneOncology acquisition [2] - The company anticipates revenue growth of 7% to 9% across its segments, with adjusted operating income growth projected at 11.5% to 13.5% [2] - The adjusted effective tax rate is expected to be around 20% for fiscal 2026, with net interest expense projected between $480 million and $500 million [2]

Core Insights - Pfizer reported solid financial results for the full year 2025, with revenues of $62.6 billion, reflecting a 2% year-over-year operational decline, but a 6% operational growth excluding COVID-19 product contributions [1][2] - The company reaffirmed its financial guidance for 2026, expecting revenues between $59.5 billion and $62.5 billion and adjusted diluted EPS in the range of $2.80 to $3.00 [1][2] - Pfizer's strategic focus includes approximately 20 key pivotal study starts planned for 2026, aimed at maximizing growth opportunities [1][2] Financial Performance - Full-year 2025 revenues were $62.6 billion, down from $63.6 billion in 2024, with a 2% operational decline [1][2] - Fourth-quarter 2025 revenues totaled $17.6 billion, a decrease of 1% compared to the prior year, with an operational decline of 3% [1][2] - Adjusted diluted EPS for 2025 was $3.22, reflecting a 4% increase from $3.11 in 2024 [1][2] Revenue Breakdown - The global biopharmaceuticals business saw a 2% decline in revenues for both the fourth quarter and full year [1][2] - Notable revenue growth was observed in products like Padcev (up 15%), Lorbrena (up 45%), and Abrysvo (up 136%) [1][2] - Significant declines were noted in Paxlovid (down 70%) and Comirnaty (down 35%) due to reduced COVID-19 infection rates and vaccination recommendations [1][2] Capital Allocation - In 2025, Pfizer invested approximately $8.8 billion in business development transactions and $10.4 billion in internal R&D projects [1][2] - The company returned $9.8 billion to shareholders through cash dividends, with no share repurchases completed in 2025 [1][2] - Pfizer's remaining share repurchase authorization as of February 3, 2026, is $3.3 billion, with no share repurchases anticipated in 2026 [1][2] Strategic Developments - Pfizer announced several key product developments, including positive Phase 3 results for Braftovi and Hympavzi, and advancements in its obesity treatment pipeline [2] - The company completed the acquisition of Metsera for approximately $7.0 billion, enhancing its portfolio in obesity and cardiometabolic diseases [2] - Pfizer also reached an agreement to exit its investment in ViiV Healthcare Limited for $1.875 billion [2]

Market Overview - Major U.S. stock indexes experienced choppy trading, ending the day mixed with the S&P 500 down 0.57 points to 6,978.03, the Dow up 12.19 points to 49,015.60, and the Nasdaq rising 40.35 points to 23,857.45 [1] - The Federal Reserve announced its decision to keep interest rates unchanged at a target range of 3.50 to 3.75 percent after three consecutive quarter-point cuts [2] - The decision to maintain rates was not unanimous, with two Fed Governors advocating for a further quarter-point cut [2][4] Economic Outlook - The Fed's decision was influenced by elevated uncertainty regarding the economic outlook, emphasizing the dual mandate of maximum employment and maintaining inflation at 2 percent over the long term [3] - A majority of the Federal Open Market Committee (FOMC) appears to favor a pause in rate cuts unless the job market weakens further, with inflation remaining a concern [4] Sector Performance - Gold stocks surged, with the NYSE Arca Gold Bugs Index increasing by 2.7 percent to a new record closing high, driven by rising gold prices [5] - The NYSE Arca Computer Hardware Index rose by 2.6 percent, also reaching a new record closing high, largely due to a 19.1 percent increase in Seagate Technology's shares following better-than-expected fiscal second-quarter results [6] - Semiconductor and networking stocks showed considerable strength, while oil service, pharmaceutical, and biotechnology stocks experienced significant declines [7] International Markets - In the Asia-Pacific region, stock markets mostly moved higher, with Japan's Nikkei 225 Index up 0.1 percent, South Korea's Kospi up 1.7 percent, and Hong Kong's Hang Seng Index up 2.6 percent [7] - Conversely, major European markets declined, with the French CAC 40 Index down 1.1 percent, the U.K.'s FTSE 100 Index down 0.5 percent, and the German DAX Index down 0.3 percent [8] Bond Market - Treasuries saw a decline in prices following the Fed announcement, leading to a rise in the yield on the benchmark ten-year note by 2.8 basis points to 4.251 percent [9] Upcoming Events - Trading on Thursday may be influenced by earnings reports from major tech companies including Microsoft, Meta Platforms, and Tesla [9]

Core Viewpoint - NetraMark Holdings Inc. has successfully closed the first tranche of a non-brokered private placement, raising gross proceeds of $3,110,000, which will be utilized for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The first tranche involved the issuance of 3,110,000 units at a price of $1.00 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional common share at an exercise price of $1.35 for a period of two years from the closing date [2]. - The securities issued are subject to a hold period expiring on May 28, 2026, as per applicable securities laws [3]. Group 2: Future Tranche and Financial Commitments - The company has received commitments for the second and final tranche of the private placement, expected to close soon for additional gross proceeds of $390,000 [4]. - Following the first tranche, there are now 91,778,520 common shares of NetraMark issued and outstanding [3]. Group 3: Insider Participation - Certain insiders participated in the first tranche, subscribing for a total of 2,060,000 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the nature of the transaction and its market capitalization [5]. Group 4: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions for the pharmaceutical industry, utilizing a novel topology-based algorithm to analyze patient data [8]. - The company's AI technology, NetraAI, is designed to improve clinical trial success rates by effectively segmenting patient data into explainable and unexplainable subsets, addressing issues of overfitting common in other AI methods [7].

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2] Group 1 - The Biotech Analysis Central service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1] - The service aims to assist healthcare investors in making informed decisions through comprehensive analysis and news reports [2] Group 2 - The author, Terry Chrisomalis, has a background in Applied Science and focuses on generating long-term value in the Healthcare sector [2] - The platform includes features such as live chat and detailed analysis for each stock in the model portfolio, enhancing investor engagement and information access [2]

Swiss pharmaceutical company Roche said that a once-weekly injection of an experimental drug known as CT-388 helped patients shed weight in a midstage clinical trial—resulting in a weight loss of 22.5% when adjusting for placebo at 48 weeks. https://t.co/1IWDsXJIWf ...